UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2546) 2546
life sciences & biomedicine (2446) 2446
humans (2214) 2214
diabetes mellitus, type 2 - drug therapy (1319) 1319
male (1237) 1237
diabetes (1109) 1109
endocrinology & metabolism (1098) 1098
type 2 diabetes (1094) 1094
female (967) 967
hypoglycemic agents - therapeutic use (946) 946
glucagon (940) 940
animals (822) 822
middle aged (749) 749
glucose (705) 705
glucagon-like peptide 1 (679) 679
insulin (675) 675
peptides (624) 624
diabetes mellitus (607) 607
hypoglycemic agents - adverse effects (574) 574
glucagon-like peptide 1 - analogs & derivatives (556) 556
liraglutide (550) 550
adult (530) 530
pharmacology & pharmacy (480) 480
treatment outcome (480) 480
glucagon-like peptide 1 - therapeutic use (459) 459
blood glucose - metabolism (458) 458
aged (452) 452
hypoglycemic agents - administration & dosage (452) 452
diabetes mellitus, type 2 - blood (419) 419
obesity (403) 403
clinical trials (368) 368
blood glucose - drug effects (364) 364
analysis (357) 357
dextrose (354) 354
glucagon-like peptide-1 receptor (349) 349
care and treatment (346) 346
abridged index medicus (344) 344
glucagon-like peptide 1 - metabolism (334) 334
glucagon-like peptide-1 (332) 332
glucagon-like peptide-1 receptor - agonists (324) 324
dipeptidyl-peptidase iv inhibitors - therapeutic use (323) 323
internal medicine (321) 321
hypoglycemic agents (319) 319
hypoglycemic agents - pharmacology (319) 319
glp-1 (318) 318
drug therapy (314) 314
risk factors (314) 314
peptides - therapeutic use (307) 307
research (295) 295
body weight (294) 294
diabetes therapy (290) 290
medicine & public health (280) 280
insulin resistance (279) 279
double-blind method (276) 276
diabetes mellitus, type 2 - metabolism (269) 269
glucagon-like peptide 1 - blood (269) 269
exenatide (262) 262
glucagon-like peptide 1 - adverse effects (259) 259
general & internal medicine (258) 258
receptors, glucagon - agonists (257) 257
health aspects (248) 248
insulin - blood (245) 245
glucagon-like peptide 1 - administration & dosage (242) 242
medicine, general & internal (241) 241
drug therapy, combination (240) 240
diabetes mellitus, type 2 - complications (239) 239
mice (239) 239
venoms - therapeutic use (235) 235
hypoglycemia (224) 224
rats (222) 222
incretins - therapeutic use (221) 221
rodents (217) 217
digestive, oral, and skin physiology (216) 216
patients (215) 215
physiological aspects (214) 214
glycated hemoglobin a - metabolism (211) 211
insulin - metabolism (210) 210
type 2 diabetes mellitus (210) 210
hyperglycemia (206) 206
glucagon-like peptide 1 - agonists (203) 203
glucagon-like peptide 1 - pharmacology (195) 195
drug administration schedule (192) 192
studies (189) 189
endocrine system (183) 183
glucose metabolism (180) 180
review (180) 180
cardiovascular system & cardiology (179) 179
metabolism (176) 176
body mass index (175) 175
dose-response relationship, drug (170) 170
peptides - adverse effects (169) 169
randomized controlled trials as topic (169) 169
obesity - drug therapy (168) 168
glycosylated hemoglobin (167) 167
peptides - administration & dosage (166) 166
body weight - drug effects (164) 164
metformin - therapeutic use (162) 162
cardiovascular disease (161) 161
metformin (160) 160
young adult (159) 159
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2969) 2969
German (27) 27
Japanese (15) 15
Spanish (13) 13
French (7) 7
Danish (5) 5
Chinese (3) 3
Korean (3) 3
Portuguese (3) 3
Russian (3) 3
Czech (2) 2
Hungarian (2) 2
Italian (2) 2
Dutch (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2009, Volume 374, Issue 9683, pp. 39 - 47
... assigned to receive additional liraglutide 1·8 mg once a day (n=233) or exenatide 10 μg twice a day (n=231) in a 26-week open-label, parallel-group, multinational... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Nausea - chemically induced | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Diabetes Mellitus, Type 2 - metabolism | Weight Loss - drug effects | Dose-Response Relationship, Drug | Glucagon-Like Peptide 1 - agonists | Injections, Subcutaneous | Female | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Drug Administration Schedule | Peptides - chemistry | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glucagon-Like Peptide 1 - chemistry | Linear Models | Logistic Models | Treatment Outcome | Hypoglycemic Agents - chemistry | Blood Glucose - drug effects | Analysis of Variance | Venoms - therapeutic use | Venoms - chemistry | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Hypoglycemic agents | Dosage and administration | Drug therapy | Molecular structure | Clinical trials | Diabetes | Clinical medicine | Apoptosis | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 04/2017, Volume 19, Issue 4, pp. 524 - 536
Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs... 
GLP‐1 analogue | type 2 diabetes | network meta‐analysis | systematic review | network meta-analysis | GLP-1 analogue | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Immunoglobulin Fc Fragments - administration & dosage | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Peptides - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Glucagon | Analysis | Diabetes therapy | Hypoglycemia | Diabetes | Systematic review | Evidence-based medicine | Index Medicus
Journal Article
Diabetes care, ISSN 1935-5548, 08/2014, Volume 37, Issue 8, pp. 2149 - 2158
OBJECTIVE To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor agonist, to sitagliptin in uncontrolled, metformin-treated patients with type 2 diabetes... 
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Double-Blind Method | Treatment Outcome | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Pyrazines - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Sitagliptin | Care and treatment | Dosage and administration | Safety and security measures | Comparative analysis | Clinical trials | Hemoglobin | Glycosylation | Diabetes | Product safety | Placebo effect | Index Medicus | Psychosocial Research | Nutrition | Education | Clinical Care
Journal Article
Diabetes care, ISSN 0149-5992, 05/2017, Volume 40, Issue 5, pp. 647 - 654
OBJECTIVE To assess the risk of acute pancreatitis during treatment with glucagon-like peptide 1 receptor agonist dulaglutide, placebo, and active comparators across phase 2/3 dulaglutide trials... 
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Metformin - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Metformin - adverse effects | Female | Immunoglobulin Fc Fragments - therapeutic use | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Hypoglycemic Agents - therapeutic use | Acute Disease | Insulin Glargine - adverse effects | Venoms - adverse effects | Insulin Glargine - therapeutic use | Pancreatitis - chemically induced | Glucagon-Like Peptides - adverse effects | Venoms - therapeutic use | Sitagliptin Phosphate - therapeutic use | Glucagon-Like Peptides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Peptides - adverse effects | Peptides - therapeutic use | Sitagliptin Phosphate - adverse effects | Risk factors | Pancreatitis | Enzymes | Peptides | Glucagon | Adjudication | Medical treatment | Diabetes mellitus | Clinical trials | Exposure | Lipase | Insulin | Patients | Incidence | Amylases | Pain | Etiology | Comparators | Risk assessment | Research design | Diabetes | Metformin | Pancreas | Glucagon-like peptide 1 | Index Medicus
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 08/2014, Volume 16, Issue 8, pp. 673 - 688
Journal Article